BMS secures expanded FDA approval for Camzyos to reduce need for SRT
Camzyos is already approved in the US, to treat adults with symptomatic New York Heart Association (NYHA) class…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Jun 23
Camzyos is already approved in the US, to treat adults with symptomatic New York Heart Association (NYHA) class…
15 Jun 23
The approval allows for the investigation of ALE.C04 both as a standalone treatment and in combination with pembrolizumab…
08 Jun 23
The EC authorisation follows the positive recommendation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
01 Jun 23
Abrysvo is a bivalent RSV prefusion F (RSVpreF) unadjuvanted vaccine that contains two preF proteins to optimise the…
26 May 23
Paxlovid is an oral SARS-CoV-2 main protease (Mpro) inhibitor therapy, containing 300mg nirmatrelvir and 100mg ritonavir at a…
25 May 23
During pre-clinical pharmacological studies, BRY812 showed considerable antitumour activity in multiple tumour models
19 May 23
The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by…
18 May 23
The task force has already set up two working groups, which will focus on childhood/young adult cancer and…
15 May 23
Veozah is a non-hormonal neurokinin 3 (NK3) receptor antagonist that blocks the activities of the NK3 receptor, which…
08 May 23
BRUKINSA is now the only new-generation BTK inhibitor in China to have been approved for the first-line treatment…